Grifols SA ADR G0FB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if G0FB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $6.25
- Day Range
- $6.25–6.35
- 52-Week Range
- $4.62–8.40
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $4.24 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 26.31
- Price/Sales
- 0.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
|
Metric
|
G0FB
|
4502
|
CSL
|
|---|---|---|---|
Price/Earnings (Normalized) | 26.31 | 15.69 | 29.83 |
Price/Book Value | 0.73 | 0.89 | 5.54 |
Price/Sales | 0.64 | 1.54 | 6.63 |
Price/Cash Flow | 7.35 | 7.51 | 34.62 |
Price/Earnings
G0FB
4502
CSL
Financial Strength
|
Metric
|
G0FB
|
4502
|
CSL
|
|---|---|---|---|
Quick Ratio | 0.63 | 0.46 | 0.95 |
Current Ratio | 2.79 | 1.06 | 2.15 |
Interest Coverage | 1.31 | 1.93 | 7.21 |
Quick Ratio
G0FB
4502
CSL
Profitability
|
Metric
|
G0FB
|
4502
|
CSL
|
|---|---|---|---|
Return on Assets (Normalized) | 1.30% | 2.86% | 8.11% |
Return on Equity (Normalized) | 4.69% | 6.13% | 18.17% |
Return on Invested Capital (Normalized) | 3.45% | 4.78% | 10.94% |
Return on Assets
G0FB
4502
CSL
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Nwnftbqpqh | Zfvs | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Rtbshytt | Tghb | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Kghbdmjqb | Hqfbk | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Kklcwybgm | Hwhq | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Ggffvsdpy | Lqtw | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Svbjldwcg | Mfn | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Hvdtwcwmc | Yzlz | $216.8 Bil | |||
| Amgen Inc
AMGN
| Fksjmcymrb | Bnsdc | $160.2 Bil | |||
| Pfizer Inc
PFE
| Xzgbdzwy | Yhc | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Lwthpcnc | Knq | $116.1 Bil |